InvestorsHub Logo
Followers 3
Posts 801
Boards Moderated 0
Alias Born 02/07/2016

Re: None

Friday, 12/02/2016 2:21:11 PM

Friday, December 02, 2016 2:21:11 PM

Post# of 8545
Simply put, the PFS with pegph20 has far exceeded Halozyme's own expectations (they projected all year long that they would have mature data by now). This is fantastic news and it is why share price went from 8's to 14's after the delay in maturity was announced at the last quarterly call. The stock has now taken a breather along with XBI and with the disappointment of Abbvie's decision. Compared to the importance/impact of Pegph20 as a potential blockbuster cancer breakthrough for various types of solid tumors, the abbvie news and the direction of XBI will be of little significance in the near future.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News